• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Thomson, David J
    Silva, Priyamal
    Denton, Kim
    Bonington, Suzanne C
    Mak, Soo K
    Swindell, Ric
    Homer, Jarrod J
    Sykes, Andrew J
    Lee, Lip W
    Yap, Beng K
    Slevin, Nicholas J
    Show allShow less
    Issue Date
    2013-12-17
    
    Metadata
    Show full item record
    Abstract
    Background There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. We evaluate sorafenib, an oral multi-kinase inhibitor, which has an attractive targeting profile for this disease. Materials and Methods In a single-arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400mg bid. Results 23 patients, median age 51 years were recruited from 2009-2011. Median progression-free and overall survivals were 11.3 and 19.6 months, respectively. Progression-free survivals at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated and 13 (57%) patients experienced grade 3 toxicity. Conclusions Sorafenib showed modest activity in ACC with a 12 month progression-free survival of 46.2%. Sorafenib 400mg bid was associated with significant toxicity and taken together with limited effectiveness cannot be enthusiastically recommended for further evaluation. Head Neck, 2013.
    Citation
    Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. 2013: Head Neck
    Journal
    Head & Neck
    URI
    http://hdl.handle.net/10541/312427
    DOI
    10.1002/hed.23577
    PubMed ID
    24346857
    Type
    Article
    Language
    en
    ISSN
    1097-0347
    ae974a485f413a2113503eed53cd6c53
    10.1002/hed.23577
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    • Authors: Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L
    • Issue date: 2016 Dec
    • Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
    • Authors: Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH, Bang YJ
    • Issue date: 2015 Aug 1
    • Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    • Authors: Couvreur K, Celine J, Marlies B, Randal D, Philippe D, Frederic D, Sylvie R
    • Issue date: 2020 Oct
    • Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
    • Authors: Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE
    • Issue date: 2016 Feb
    • Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
    • Authors: Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF
    • Issue date: 2020 Jan 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.